| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Treatment of THP-1 cells and bone marrow macrophages with metaproterenol (10 μM; 74 hours) improves high glucose-induced β-arrestin2 and its association with IκBα [1]. Treatment with isoproterenol (10 μM; 74 hours; THP-1 cells and bone marrow macrophages) causes a significant downregulation of NF-κB in response to high glucose [1].
|
|---|---|
| ln Vivo |
Metaproterenol treatment for 12 weeks reduced monocyte activation and pro-inflammatory and pro-fibrotic responses in the kidney and heart of Zucker diabetic adipose rats. Consequently, metaproterenol may protect against renal and cardiovascular problems associated with diabetes [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: THP-1 cells and bone marrow macrophages Tested Concentrations: 10 μM Incubation Duration: 74 hrs (hours) Experimental Results: Enhanced β-arrestin2 and its interaction with IκBα. RT-PCR[1] Cell Types: THP-1 cells and bone marrow macrophages Tested Concentrations: 10 μM Incubation Duration: 74 hrs (hours) Experimental Results: Result in downregulation of NF-κB. |
| References |
|
| Additional Infomation |
Metaproterenol Sulfate is the sulfate salt form of metaproterenol, a short-acting and selective sympathomimetic beta-receptor agonist with bronchodilator activity. Metaproterenol sulfate binds beta-2 adrenergic receptors in bronchial smooth muscle and stimulates intracellular adenyl cyclase, thereby increasing the production of cyclic adenosine monophosphate (cAMP). Increased cAMP levels cause relaxation of bronchial smooth muscle, improve mucocliary clearance and reduce inflammatory cell mediator release, especially from mast cells.
A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM. |
| Molecular Formula |
2[C11H18NO3+].O4S-2
|
|---|---|
| Molecular Weight |
520.59364
|
| Exact Mass |
520.209
|
| CAS # |
5874-97-5
|
| Related CAS # |
Metaproterenol;586-06-1;Metaproterenol-d7 hemisulfate
|
| PubChem CID |
441333
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.199g/cm3
|
| Boiling Point |
417.5ºC at 760mmHg
|
| Melting Point |
202-203°
|
| Flash Point |
179.7ºC
|
| LogP |
3.468
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
35
|
| Complexity |
258
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MKFFGUZYVNDHIH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/2C11H17NO3.H2O4S/c2*1-7(2)12-6-11(15)8-3-9(13)5-10(14)4-8;1-5(2,3)4/h2*3-5,7,11-15H,6H2,1-2H3;(H2,1,2,3,4)
|
| Chemical Name |
5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,3-diol;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~240.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.99 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9209 mL | 9.6045 mL | 19.2090 mL | |
| 5 mM | 0.3842 mL | 1.9209 mL | 3.8418 mL | |
| 10 mM | 0.1921 mL | 0.9604 mL | 1.9209 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
